DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

272BIO Limited

Reading, United Kingdom
20 profile visits

About

272BIO is a UK-Belgium based antibody discovery and development company with full in-house CMC process development capability. The company is focused and has a track-record of developing differentiated products with a competitive advantage for indications and opportunities across animal health

Areas of Activity

Agro-FoodBiotech/BiopharmaInvestment

Representatives

Charles Owen

CEO / Founder 272BIO

272BIO Limited

Christine Labeur

Head of Development

272BIO Limited